Puerto Rico conference delivers essentials of bio/pharma cleanroom design and operation

10/01/2005

SAN JUAN, PR - The essentials of designing, constructing, qualifying and operating a pharmaceutical cleanroom will be presented by internationally recognized contamination-control expert Dr. Hans Schicht at CleanRooms Puerto Rico, November 17, at the Wyndham Condado Plaza Hotel & Casino. Dr. Schicht has given seminars and presented lectures on cleanroom technology topics in many countries around the world. He represents Switzerland on ISO/TC 209 and CEN/TC 243, the technical committees responsible for international and European standardization in the cleanroom technology field, and he was executive secretary of the Swiss Society for Contamination Control (SRRT) for the years 1994-2004.

Completion of Dr. Schicht’s course will convey attendees with a certificate attesting to their having gained the competence and background knowledge for assuming responsible positions within the contamination-control field. During the four sessions, training will include: determining cleanliness zoning concepts; elaborating and optimizing the layout of clean facilities; preparing basic specifications and qualification master plans for cleanroom systems; evaluating and assessing technical proposals; developing qualification strategies; and understanding essential standards and regulatory requirements for contamination control in facilities producing sterile and nonsterile pharmaceutical products and medical devices.

CleanRooms Puerto Rico will also include industry exhibits showcasing the latest in contamination-control technology and products.

With its economy strongly oriented toward advanced manufacturing, Puerto Rico is an international hub for bio/pharmaceutical manufacturing. Global sales of 54 bio/pharmaceutical drugs manufactured on the island reached $37 billion in the first half of 2004. Sixteen of the top twenty pharmaceuticals sold in the U.S. are also manufactured in Puerto Rico by such companies as Amgen, Ortho, Bristol-Myers Squibb, and Eli Lilly. Puerto Rico is also being seen as a key location for new bio/pharmaceutical development, with an expansive new $12.5 million biotechnology center and pilot plant evaluation facility being constructed on the island.

For more information or to register for CleanRooms Puerto Rico, visit: www.cleanrooms.com